New research examines how alcohol exposure impacts aspects of neuroplasticity
New research and analysis examine how alcohol exposure impacts many aspects of neuroplasticity in a special issue of
Brain Plasticity
Neuroplasticity, the remarkable ability of the brain to modify and reorganize itself, is affected by or in response to excessive alcohol, whether through individual consumption or exposure in the womb.
It is now well accepted that the birth and integration of new neurons continue beyond development and into adulthood. New discoveries and insights on how alcohol impacts this and other plastic processes are discussed in Alcohol and Neural Plasticity, a special issue of
E-Mail
IMAGE: Neural plasticity, the remarkable ability of the brain to modify and reorganize itself at the synapse, circuit and cellular levels is affected by and/or in response to excessive alcohol intake. view more
Credit: Steven P. Guerin
Amsterdam, NL, February 10, 2021 - Neuroplasticity, the remarkable ability of the brain to modify and reorganize itself, is affected by or in response to excessive alcohol, whether through individual consumption or exposure in the womb. It is now well accepted that the birth and integration of new neurons continue beyond development and into adulthood. New discoveries and insights on how alcohol impacts this and other plastic processes are discussed in Alcohol and Neural Plasticity, a special issue of
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.